Obesity is a chronic metabolic disorder caused by an imbalance between energy intake and expenditure. It is a major known risk factor for many chronic diseases such as type 2 diabetes, hypertension and atherosclerosis.
Obesity is a chronic metabolic disorder caused by an imbalance between energy intake and expenditure. It is a major known risk factor for many chronic diseases such as type 2 diabetes, hypertension and atherosclerosis. 1) Therefore, it has become a major obstacle of improving human health and life quality. Obesity is characterized by a pathologic growth of adipose tissues, which is intrinsically a consequence of adipocyte hypertrophy and differentiation. 2) Studies on several established immortal preadipocyte cell lines such as 3T3-L1 and 3T3-F442A have greatly facilitated our understanding of adipocyte differentiation, which is a tightly controlled and highly orchestrated event accompanied by expression of multiple transcription factors and adipogenic markers, including the CCAAT/enhancer binding proteins (C/EBPs), the peroxisome proliferator-activated receptors (PPARs), fatty acid synthase (FAS) and the adipocyte-specific fatty acid binding protein (aP2). 3, 4) Briefly, growth-arrested preadipocytes reenter the cell cycle and undergo one or two rounds of division known as mitotic clonal expansion (MCE), during which an immediate and transient induction of C/EBPb and C/EBPd occurs and is followed by up-regulation of PPARg and C/EBPa, two master transcription factors of adipogenesis. PPARg and C/EBPa further trigger expression of multiple adipogenic genes that synergistically lead to adipocyte phenotype. 4) Tang et al. reported that MCE was a prerequisite for adipogenesis and C/EBPb was required for MCE, 5, 6) suggesting the importance of C/EBPb in the initial stage of adipocyte differentiation.
AMP-activated protein kinase (AMPK), a serine/threonine kinase consisting of a catalytic subunit a and two regulatory subunits b and g, plays a key role in regulation of fatty acid and glucose homeostasis. 7) AMPK activation requires phosphorylation at Thr172 of AMPKa subunit by upstream AMPK kinase. Once activated, AMPK blocks ATP-consuming pathways and stimulates ATP-generating pathways. AMPK acts via phosphorylation of downstream metabolic enzymes and transcription factors. 8) Acetyl-CoA carboxylase (ACC), a critical enzyme for lipid biosynthesis, can be phosphorylated and inactivated by AMPK. 9) Inactivation of ACC leads to a decreased production of malonyl CoA, which in turn de-represses carnitine palmitoyl-CoA transferase (CPT1) to increase fatty acid oxidation. 10) Previous studies have demonstrated the involvement of AMPK activation in the anti-adipogenic effects of several compounds. 11, 12) On the other hand, low-level activation of AMPK is likely to play a role in the development of obesity and diabetes. 13) Hence, the function of AMPK activation in adipogenesis needs further investigation.
A-769662 is a novel activator of AMPK which activates AMPK directly in vivo and in vitro. 14, 15) Previous research demonstrated that A-769662 reduced body weight gain and decreased liver and plasma triglyceride levels via increasing fatty acid oxidation and reducing fatty acid synthesis in vivo. 14) However, the effect of A-769662 on adipocyte differentiation was hitherto unknown. In this study, we examined the effects of A-769662 on adipogenic differentiation of 3T3-L1 cells. We found that A-769662 significantly inhibited 3T3-L1 adipogenesis in several ways, of which the over-activation of AMPK by this compound may be the major one. 14) and dissolved in DMSO. All primary antibodies were purchased from Cell Signaling Technology.
MATERIALS AND METHODS

Materials
3T3-L1 Differentiation and Oil Red O Staining Growth-arrested 3T3-L1 preadipocytes were cultured in differentiation medium containing 5 mg/ml insulin (Sigma), 1 mM dexamethasone (Sigma), and 0.5 mM isobutylmethylxanthine (Calbiochem). The day when cells were initiated for differentiation is designated as Day 0. The medium was changed to DMEM containing 5 mg/ml insulin 2 d later. Cells were then cultured in normal medium since Day 4 and the process of differentiation proceeded until Day 8, when preadipocytes became mature adipocytes. Cells on Day 8 were fixed in fresh formalin solution and stained with Oil Red O dye (Amresco). The lipid staining was quantified by extracting the dye with isopropanol and determining the absorbance at 500 nm.
Quantitative Real-Time PCR Total RNA was extracted from cells using TRIzol Reagent (Invitrogen). First-strand cDNA was synthesized using Superscript TM III Reverse Transcriptase (Invitrogen) and mRNA levels of target genes were measured by quantitative Real-Time PCR (RT-PCR). All RT-PCR primers used in this study were described previously. 16) Western Blotting Cells were lysed in ice-cold lysis buffer (50 mM Tris, 150 mM NaCl, 2 mM ethylene diaminetera acetic acid, 1 mM phenylmethyl sulfonyl fluoride, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM NaF, 1 mM sodium orthovanadate, 15 mM Na 4 P 2 O 7 and 10 mM b-glycerophosphate). Cell lysate was separated via electrophoresis on an 8% SDS-polyacrylamide gel, followed by electrophoretic transfer to PVDF membrane (Millipore). Target proteins were detected using a chemiluminescence kit (Pierce).
Luciferase Reporter Gene Assay HEK293 cells were co-transfected with PPARg-LBD plasmid, which expresses a fusion protein composed of the DNA-binding domain of the yeast protein GAL4 at the N-terminus and the ligand binding domain of PPARg at the C-terminus, and pFR-Luc plasmid, which is the luciferase reporter vector containing a synthetic promoter with five tandem repeats of the yeast GAL4 binding sites. Similarly, HEK293 cells were transfected with pGL3-aP2 plasmid, which contains an aP2 promoter directing the expression of the luciferase gene. Six hours later cells were treated with 20 mM rosiglitazone in the presence of various concentrations of A-769662 for 24 h followed by determination of luciferase activity using a luciferase assay kit (Promega).
SYTOX Green Nucleic Acid and DAPI Staining Cell viability was determined using SYTOX Green (Invitrogen), a nucleic acid dye that readily penetrates cells with compromised plasma membranes but not cells with intact membranes. Unviable cells show an intense fluorescence after SYTOX Green staining. 17) Total cell number was indicated by DAPI (Amresco) staining. Cells were co-stained with 1 mM SYTOX Green and 50 mg/ml DAPI for 30 min at 37°C and photographed on a fluorescent microscope.
Statistical Analysis Results in this study were shown as meanϮS.D. of at least three independent experiments. Statistical significance was determined using the two-tail Student's t test and a value of pϽ0.05 was considered significant. fect on 3T3-L1 adipogenesis while 1.2 mM A-769662 almost completely blocked this process (Fig. 1B ). This result was further supported by quantification of the lipid staining (Fig.  1C) .
RESULTS
A-769662 Inhibited 3T3-L1 Adipogenesis
A-769662 Inhibited the Expression of AdipogenesisRelated Transcription Factors and Markers 3T3-L1 adipogenic differentiation requires synergistic action of multiple transcription factors and adipogenic markers including PPARg, C/EBPa, aP2 and FAS. 4) Among them, PPARg and C/EBPa are two key transcription factors which are up-regulated and work cooperatively to enhance the expression of several other adipogenic markers such as aP2 and FAS. As shown in Fig. 2A , the up-regulation of PPARg and C/EBPa was largely abrogated upon treatment with A-769662. Similar effects on the expression of aP2 and FAS were also observed. Moreover, transcriptional activity of PPARg in response to rosiglitazone was significantly inhibited by A-769662 treatment. Up-regulation of aP2 induced by rosiglitazone was also suppressed by A-769662 treatment in a dosedependent manner (Fig. 2B) . This result further supported the inhibitory effects of A-769662 on key transcription factors and adipogenic markers during 3T3-L1 differentiation.
The effects of A-769662 on C/EBPb and C/EBPd, two transcription factors upstream of PPARg and C/EBPa, were next examined. Similarly, A-769662 was shown to exert an inhibitory effect on expression of both C/EBPb and C/EBPd (Fig. 2C) Fig. 3B) . Since mitotic clonal expansion (MCE) was a prerequisite for 3T3-L1 differentiation, 5) whether A-769662 affected proliferation of preadipocyte was next examined during the induction stage of differentiation. As shown in Fig. 3C , while number of control cells increased 2.5-fold from Day 0 to Day 3, the number of 3T3-L1 cells treated with 1.2 mM A-769662 remained largely unchanged. This result demonstrated that A-769662 inhibited 3T3-L1 differentiation at least partly via inhibition of MCE. Results obtained with 0.6 mM A-769662 further supported this notion. As 0.6 mM A-769662 only partly blocked MCE, it had only a moderate inhibitory effect on 3T3-L1 differentiation.
A-769662 Decreased Cell Viability of Differentiating and Mature 3T3-L1 Adipocytes A-769662 was found to decrease cell viability of 3T3-L1 adipocytes while the growth of 3T3-L1 preadipocytes was largely unaffected at the same concentration of the compound (Fig. 3D) . In addition, a positive correlation seemed to exist between the degree of 3T3-L1 differentiation and the susceptibility of the cells to A-769662. Mature 3T3-L1 adipocytes (cells on Day 8) were most sensitive to A-769662 and a large portion of cells died after a two-day treatment with the compound. This result was further supported by determining the rates of SYTOX Green positive cells (Fig. 3E) . Furthermore, cell viability on each day during the process of MCE was examined by co-staining cells with SYTOX Green and DAPI and measuring the rates of SYTOX Green negative cells. The result showed that A-769662 exerted little inhibitory effect on 3T3-L1 cell viability from Day 0 to Day 3 of differentiation (Fig.  3F) .
Enhanced AMPK Activity Was Involved in the Inhibitory Effects of A-769662 on 3T3-L1 Adipogenesis Since A-769662 is a specific activator of AMPK, whether AMPK is activated by A-769662 during 3T3-L1 differentia- tion was then examined. Specifically, the levels of phosphorylated ACC and AMPKa, which represent the enzymatic activity of AMPK and the activated conformation of AMPK respectively, were analyzed and compared with the total levels of ACC and AMPKa. As shown in Fig. 4 , the total and phosphorylated ACC increased remarkably at the mid and late stage of 3T3-L1 differentiation and this enhancement was almost completely abrogated when 3T3-L1 cells were treated with 1.2 mM A-769662. The protein level of ACC remained largely unchanged in 3T3-L1 cells treated with 1.2 mM A-769662, still the protein level of p-ACC was kept at a relatively high level, indicating that AMPK activity was greatly increased by 1.2 mM A-769662 during 3T3-L1 differentiation. The level of total AMPKa appeared relatively constant during 3T3-L1 differentiation in the presence or ab- sence of A-769662. In contrast, the level of phosphorylated AMPKa increased gradually and was further enhanced by the treatment of different concentration of A-769662 during 3T3-L1 differentiation. Therefore, these results indicated that AMPK was moderately activated during 3T3-L1 differentiation and treatment with 1.2 mM A-769662 rendered AMPK to be in a fully activated state, which was detrimental to 3T3-L1 differentiation.
DISCUSSION
Understanding the molecular mechanisms controlling adipocyte differentiation is critically important for potential pharmacological intervention and treatment of obesity. AMP-activated protein kinase (AMPK), a fuel-sensing enzyme that plays a key role in the regulation of carbohydrate and fat metabolism and a potential drug target for the treatment of obesity and diabetes, appears to be intimately involved in adipocyte differentiation and maturation. 8) Particularly, low-level activation of AMPK was suggested to play a role in the pathogenic development of obesity and diabetes. 13) In the present study, we examined the effects of a novel AMPK activator, A-769662 on adipogenic differentiation of 3T3-L1 cells. A-769662 significantly activated AMPK in 3T3-L1 preadipocytes, and effectively inhibited 3T3-L1 adipogenesis. It is notable that the concentration of A-769662 used in this study was much higher than that reported previously, 14, 15) which is likely explained by a different sensitivity of the cell type used. Indeed, we found that 3T3-L1 cells were much more tolerable to A-769662 than other cell types such as HEK293 in our experiments (data not shown). A-769662 significantly inhibited the up-regulation of PPARg and C/EBPa, two master regulators of adipogenesis, indicating that A-769662 might inhibit 3T3-L1 differentiation via suppressing the expression of adipogenesis-related transcription factors and markers. Down-regulation of late adipogenic markers including aP2 and FAS by A-769662 further supported this speculation. Meanwhile, PPARg transcriptional activity was significantly reduced, suggesting that A-769662 down-regulated PPARg expression as well as its transcriptional activity. It has been reported that phosphorylation of the transcriptional coactivator p300 by AMPK dramatically reduced its interaction with PPARg.
18) The PPARg coactivator-1 (PGC-1) was also implicated to be directly phosphorylated by AMPK in skeletal muscle. 19) We suppose that A-769662 might repress the transcriptional activity of PPARg via activating AMPK and phosphorylating PPARg coactivators and hence leading to the inhibition of their abilities to interact with PPARg. In addition, it is likely that A-769662 could also inhibit the expression of aP2, which might be an indirect result of decreased PPARg transcriptional activity since PPARg is an upstream regulator of aP2. Furthermore, the transient up-regulation of C/EBPb and C/EBPd, which appeared on the early phase of differentiation and induced the expression of PPARg and C/EBPa, 3) was also significantly inhibited by A-769662. Overall, these results demonstrated that A-769662 inhibited 3T3-L1 differentiation via exerting an inhibitory effect on the signaling cascade that ultimately culminated in adipogenesis.
Though A-769662 displayed an inhibitory effect on the whole process of differentiation, it inhibited differentiation mainly at the early proliferation stage, which might result from inhibition of mitotic clonal expansion (MCE). Previous studies have identified that MCE was essential for 3T3-L1 differentiation. When MCE was inhibited by UO126, a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) inhibitor, 3T3-L1 adipogenesis was blocked.
5) A-769662 had similar inhibitory effect on MCE of 3T3-L1 cells, which could be attributed to a down-regulation of C/EBPb by the compound as C/EBPb was implicated to be essential to MCE during adipogenesis. 6) A latest paper demonstrated that A-769662 was able to inhibit proteasomal function and lead to an arrest of cell cycle progression in an AMPK-independent mannar in mouse embryonic fibroblast (MEF) cells. 20) Therefore, we couldn't rule out the possibility that A-769662 inhibited MCE via inhibition of proteasome activity in 3T3-L1 cells, which needs further investigation.
We speculated that AMPK activation was involved in the inhibitory effects of A-769662 on MCE and adipogenesis since AMPK activation has been reported to inhibit cell proliferation 21, 22) and adipocyte differentiation. 11, 12) Indeed, AMPK underwent a moderate activation during the process of differentiation. A-769662 treatment further enhanced this activation, leading to an increased phosphorylation and inactivation of ACC. Low concentration of AICAR (5-aminoimidazole-4-carboxamide-1-b -D-ribofuranoside), another widely used AMPK activator, also increased the phosphorylation of ACC and AMPKa during 3T3-L1 differentiation, but high concentrations of AICAR did not have this effect. 23) In contrast, there was an enhancing effect on AMPK activation for both low and high concentrations of A-769662. Probably this difference between AICAR and A-769662 is due to their different mechanisms of inhibiting 3T3-L1 differentiation since A-769662 is a more potent and specific AMPK activator than AICAR. 15) A-769662 activates AMPK directly in vivo and in vitro, 15, 24) while AICAR activates AMPK via production of ZMP which mimics the effects of AMP on AMPK activation in cells. AICAR has been implicated to regulate other AMPsensitive enzymes and activate adenosine receptors, 25, 26) but A-769662 doesn't have these side effects. We propose that a modest AMPK activity is essential to adipogenesis, but overactivation of AMPK by A-769662 inhibits 3T3-L1 differentiation as the cells sense it as a signal of energy depletion, and hence, switches off ATP-consuming anabolic pathways including synthesis of fatty acids.
AMPK activation has been implicated to suppress cell proliferation in several cell lines through different ways. HepG2 cell growth was found to be suppressed by AMPK via p53 phosphorylation. 27 ) AMPK activation with AICAR was shown to inhibit growth and proliferation in cardiac fibroblasts, which involved inhibitory interactions between ERK and AMPK. 21) Zhuang and Miskimins reported that Metformin caused cell cycle arrest via activation of AMPK, which led to loss of cyclin D1 and hence the release of sequestered CDK inhibitors, p27
Kip1 and p21 Cip1 . 28) A latest study revealed AMPK inhibited neural stem cell growth by down-regulating phospho-retinoblastoma protein (Rb) and cyclin D. 29) Thus AMPK might have different targets when regulating cell growth in different cell types. Our results have demonstrated that A-769662 inhibited clone expansion probably by inhibiting the expression of C/EBPb, which was a prerequisite for MCE, but the detailed mechanism by which AMPK inhibits MCE of 3T3-L1 cells requires further study.
Decrease of adipose tissues can result from the following: (1) inhibition of adipocyte differentiation and (2) loss of fat cells through programmed cell death. 30) Several anti-obesity compounds were shown to mediate depletion of fat mass through apoptotic pathways. 11, 31) In addition to its inhibitory effects on 3T3-L1 differentiation, A-769662 also caused a decreased cell viability of mature adipocytes. Fully differentiated 3T3-L1 adipocytes were more sensitive to the treatment of A-769662 than less differentiated 3T3-L1 cells. Probably the hydrophobic nature of A-769662 makes it readily concentrated in lipid droplets of the differentiated adipocytes and thus prolongs its inhibitory effects and accounts for this difference. This result suggests that the inhibitory action of A-769662 on adipogenesis was partly due to its ability to kill differentiated and differentiating cells while leave undifferentiated cells alone.
It's quite likely that the cytotoxic effect of A-769662 on 3T3-L1 adipocyte is also due to AMPK activation, because in F442a adipocyte cells AMPK activation by AICAR has been shown to phosphorylate the a-subunit of the eukaryotic initiation factor-2 (eIF2a), which resulted in inhibition of the synthesis of cellular survival proteins and subsequent metabolic stress that contribute to apoptosis and cell death. 32) Another possible mechanism by which A-769662 induces cell death is inhibition of the proteasome function which led to the accumulation of pro-apoptotic proteins and the down-regulation of anti-apoptotic factors. 20) In conclusion, we have investigated the inhibitory effects of A-769662 on 3T3-L1 adipogenesis for the first time. A-769662 inhibited 3T3-L1 adipogenic differentiation in three ways: (1) by down-regulating the expression of C/EBPb and C/EBPd and hence inhibiting mitotic clonal expansion, and subsequently blocking the expression of PPARg, C/EBPa and downstream adipogenic genes which are essential to the adipocyte phenotype; (2) by activating AMPK and hence phosphorylating and inactivating ACC which is essential for lipid biosynthesis; (3) by decreasing cell viability of differentiating and mature 3T3-L1 adipocytes. We proposed that all these effects were due to AMPK over-activation caused by A-769662, as AMPK has been reported to cause cell cycle arrest, and it has also been reported to cause cell apoptosis and cell death. Our results suggest that A-769662 is a potentially effective compound for the intervention and treatment of obesity and other associated diseases.
